Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Lorcaserin Stories

17725ca7200c4b9d003891545b26401b
2010-07-13 06:20:49

Doctors are getting their first glimpse at a new weight loss drug this week. The doctors hope that the drug, which is one of three new weight loss drugs coming out, can succeed where many others have failed by delivering significant weight loss without risky side effects. With U.S. Obesity rates closing in at 35 percent of the adult population, expectations are high for the first new prescription drug therapies that have been emerging for over a decade.  Even a modestly effective drug...

abca7702ad63784edcd4b0c59eae4842
2010-07-09 08:25:00

The first of three new fat-fighting drugs will face public examination by US regulatory advisers next week, as pharmaceutical companies target the growing number of overweight Americans despite a less than glamorous past for weight-loss pills. Three drug makers -- Vivus Inc, Arena Pharmaceuticals Inc and Orexigen Therapeutics Inc -- are trying to succeed where other efforts have failed after several weight-loss drugs were linked to serious and dangerous side effects. The Food and Drug...

2010-07-01 02:00:00

SAN DIEGO, July 1, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight...

2010-06-26 09:00:00

ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity and starting body weight and Body Mass Index (BMI). Greater improvements in cardiovascular risk factors were also achieved with...

2010-06-17 07:00:00

SAN DIEGO, June 17, 2010 -- /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that new data analyses from lorcaserin's pivotal Phase 3 clinical trial program will be presented in poster sessions at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida. The two posters highlighted below will be displayed in the Poster Hall from June 26, 2010, at 10:00 a.m. Eastern Time (ET) until June 28, 2010, at 4:00 p.m. ET. - Changes in...

2010-06-04 16:45:00

SAN DIEGO, June 4, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company at two upcoming investor conferences in New York City: -- Jefferies 2010 Global Life Sciences Conference ------------------------------------------------- Presentation: Wednesday, June 9, 2010, at 9:00 a.m. Eastern Time (6:00 a.m. Pacific...

2010-06-03 07:00:00

SAN DIEGO, June 3, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into an agreement with Deerfield Management, a leading healthcare investment organization, to provide Arena with approximately $35.5 million through an equity investment. Under the terms of this financing, Arena will receive gross proceeds of approximately $35.5 million from the sale of 11 million shares of its common stock to Deerfield at a price of $3.23 per...

2010-06-02 07:00:00

SAN DIEGO, June 2, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the US Food and Drug Administration (FDA) has notified the company of the tentative scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application (NDA). Lorcaserin is Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance...

2010-05-07 06:30:00

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the first quarter ended March 31, 2010. Arena reported a lower net loss in the first quarter of 2010 of $31.3 million, or $0.33 per share, compared to a net loss in the first quarter of 2009 of $50.6 million, or $0.68 per share. "We believe that lorcaserin represents a significant medical and commercial opportunity based on the drug candidate's unique combination of...

2010-05-06 07:00:00

SAN DIEGO, May 6, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Ninth Annual JMP Securities Research Conference on Tuesday, May 11, 2010, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) at The Ritz-Carlton in San Francisco. Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, is scheduled to provide an overview of the company, including its clinical development and...